Company intelligence / Profile preview

Westlake Village Partners

Westlake Village, California, United States

Ownership: Private
Development stage: Other

Overview

Westlake BioPartners has raised over $1.3 billion since 2018, launched/invested in more than 20 biotech startups, several of which have reached IPO, major partnerships, or acquisition. Notable portfolio results include Capsida Biotherapeutics partnerships with AbbVie and Eli Lilly, and Acelyrin raising $540 million through IPO in 2023.

Therapeutic areas: NephrologyCardiovascularImmunologyNeurologyRare DiseasesOncology
Modalities: Gene therapyCell therapyMonoclonal antibodySmall moleculeRNA therapymRNA-based drugsRecombinant proteinPeptidesAntibody-drug conjugateBiologicAdditional modalities via portfolio companies
Industry: Investors

Partnerships

Capsida Bio (with AbbVie and Eli Lilly)Tmunity (acquired by Gilead)

Beyond the preview

Go deeper on Westlake Village Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Westlake Village Partners.

Explore the full profile